TrialNature medicine2022

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.

Edward S Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.